The role of taxanes in triple-negative breast cancer: literature review

Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. The ongoing trials will give further information on the better management of this type of tumor.

[1]  F. Su,et al.  Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[2]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[3]  J. Sachdev,et al.  Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC). , 2013 .

[4]  J. Parker,et al.  A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. , 2015 .

[5]  V. Roy,et al.  Phase II trial of weekly nab ( nanoparticle albumin-bound )-paclitaxel ( nab-paclitaxel ) ( Abraxane ) in combination with gemcitabine in patients with metastatic breast cancer ( N 0531 ) , 2009 .

[6]  S. Isakoff,et al.  Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents , 2010, Cancer journal.

[7]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Mintzer,et al.  Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. , 2012, Clinical breast cancer.

[10]  D. Berry,et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Robert,et al.  Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. , 2007, Clinical breast cancer.

[13]  D. Yardley.  nab-Paclitaxel mechanisms of action and delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[14]  V. Valero,et al.  Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial , 2012, Breast Cancer Research and Treatment.

[15]  P. Fasching,et al.  Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials , 2010, Breast Cancer Research and Treatment.

[16]  B. Xu,et al.  Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[19]  Terry L. Smith,et al.  Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Kurosumi,et al.  Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. , 2011, Experimental and therapeutic medicine.

[21]  P. Liu,et al.  Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[22]  G. Hortobagyi,et al.  Optimal schedule of paclitaxel: weekly is better. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  James A Young,et al.  Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.

[24]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Caldas,et al.  Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[26]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  K. Blackwell,et al.  Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. , 2013, Clinical breast cancer.

[28]  G. Trifirò,et al.  Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life , 2015, Drug design, development and therapy.

[29]  W. Weichert,et al.  Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy , 2009, Breast Cancer Research.

[30]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Jeff Myers,et al.  Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. , 2009, Clinical breast cancer.

[32]  J. Hainsworth,et al.  A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer , 2007 .

[33]  W. Gradishar,et al.  Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. , 2012, Clinical breast cancer.

[34]  R. Frelick.  Cancer and leukemia group B (CALGB). , 1979, Delaware medical journal.

[35]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[36]  Guangyu Liu,et al.  Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer , 2015, International journal of nanomedicine.

[37]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[38]  Larry Norton,et al.  HER2 and response to paclitaxel in node-positive breast cancer. , 2007, The New England journal of medicine.

[39]  O. Garrone,et al.  The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines , 2015, Investigational New Drugs.

[40]  N. Rahman,et al.  Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012) , 2015 .

[41]  V. Roy,et al.  Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  S. Glück,et al.  Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer , 2012, Case Reports in Oncology.

[43]  C. Perou,et al.  Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  In Italia,et al.  Associazione Italiana di Oncologia Medica , 1997 .

[46]  S. Barni,et al.  Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel , 2010, Expert opinion on pharmacotherapy.

[47]  J. Blohmer,et al.  Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[49]  Y. Im,et al.  Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  C. Perou,et al.  Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[52]  D. Doval,et al.  Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[53]  E. Perez,et al.  Abstract P3-11-16: S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131) , 2015 .

[54]  J. Slingerland,et al.  Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer , 2010, Breast Cancer Research and Treatment.

[55]  A. Schneeweiss,et al.  Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69 , 2015 .

[56]  Tanja Fehm,et al.  Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.

[57]  A. Luini,et al.  Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel , 2008, Cancer Chemotherapy and Pharmacology.

[58]  M. Rezai,et al.  Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. , 2015 .

[59]  Masayuki Yoshida,et al.  The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype , 2011, Cancer Chemotherapy and Pharmacology.

[60]  D. Berry,et al.  Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). , 2015 .

[61]  G. Hortobagyi,et al.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  F. André,et al.  Bevacizumab: the phoenix of breast oncology? , 2015, The Lancet. Oncology.

[63]  E. Perez,et al.  Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  W. Gradishar,et al.  Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  N. Harbeck,et al.  Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. , 2015 .

[66]  A. Tan,et al.  Triple-negative breast cancer: molecular subtypes and new targets for therapy. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[67]  F. André,et al.  Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  M. Parmar,et al.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. , 2013, The Lancet. Oncology.

[69]  D. Miles,et al.  Abstract P6-12-03: Meta-Analysis of Patients with Triple-Negative Breast Cancer (TNBC) from Three Randomized Trials of First-Line Bevacizumab (BV) and Chemotherapy Treatment for Metastatic Breast Cancer (MBC) , 2010 .

[70]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  E. Winer,et al.  Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[73]  D. Ghersi,et al.  Taxane-containing regimens for metastatic breast cancer. , 2015, The Cochrane database of systematic reviews.

[74]  Zhaohui J. Cai,et al.  Pretreatment data is highly predictive of liver chemistry signals in clinical trials , 2012, Drug design, development and therapy.

[75]  M. van Engeland,et al.  Characteristics of triple-negative breast cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[76]  S. Nayler,et al.  Triple Negative Breast Cancer Pathologic Diagnosis and Current Chemotherapy Treatment Options , 2014 .

[77]  S. Steinberg,et al.  Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  H. Wildiers,et al.  Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer , 2013, Breast Cancer Research.

[79]  W. Gradishar,et al.  nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis , 2013, Breast Cancer Research and Treatment.

[80]  C. Geyer,et al.  Pathological complete response in breast cancer – Authors' reply , 2015, The Lancet.

[81]  Mauro D'Amico,et al.  Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[83]  N. Magné,et al.  Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials , 2012, Breast Cancer Research and Treatment.

[84]  A. Shakir.  Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer , 2014, Case Reports in Oncology.